MMP1 and amyotrophic lateral sclerosis: This might include continuous outcomes such aslog10-transformed total kidney volume (Torres et al. 2012), disease severityscores such as the Amyotrophic Lateral Sclerosis Functional RatingScale-Revised (Paganoni et al.2020), body mass index (Attia et al. 2019), carotid intima-mediathickness (Kastelein et al.2007), biomarkers such as log10-transformedC-reactive protein degraded by matrix metalloproteinases 1 and 8(Maher et al. 2019),or variables measuring lung function such as forced expiratoryvolume (McCormack et al.2011) or forced vital capacity (Raghu et al. 2018).